Recombinant Human Galectin-3 protein(LGALS3) (Active)

In Stock
Code CSB-AP000481HU
Size US$1637Purchase it in Cusabio online store
(only available for customers from the US)
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity >98% as determined by SDS-PAGE and HPLC.
Endotoxin Less than 1.0 EU/μg as determined by LAL method.
Activity Fully biologically active when compared to standard. The ED50 as determined by its ability to agglutinate human red blood cells is less than 10 μg/ml.
Target Names LGALS3
Uniprot No. P17931
Research Area Neuroscience?
Alternative Names 35 kDa lectin; Carbohydrate binding protein 35; Carbohydrate-binding protein 35; CBP 35; CBP35; Gal-3; GAL3; Galactose-specific lectin 3; Galactoside-binding protein; GALBP; Galectin 3 internal gene,included; Galectin-3; Galectin3; GALIG; GBP; IgE binding protein; IgE-binding protein; L 31; L 34; L-31; L-34 galactoside-binding lectin; L31; Laminin-binding protein; Lectin L-29; Lectin, galactose binding, soluble 3; LEG3_HUMAN; LGALS2; LGALS3; MAC 2 antigen; Mac-2; Mac-2 antigen; MAC2; Macrophage galactose-specific lectin; MGC105387
Species Homo sapiens (Human)
Source E.Coli
Expression Region 2-250aa
Mol. Weight 26.0 kDa
Protein Length Full Length of Mature Protein
Tag Info Tag-Free
Form Lyophilized powder
Buffer Lyophilized from a 0.2 μm filtered 1 × PBS, pH 7.4, 3mM DTT
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
and FAQs
Protein FAQs
Storage Condition Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time Basically, we can dispatch the products out in 5-10 working days after receiving your orders. Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA Please contact us to get it.

Target Data

Function Galactose-specific lectin which binds IgE. May mediate with the alpha-3, beta-1 integrin the stimulation by CSPG4 of endothelial cells migration. Together with DMBT1, required for terminal differentiation of columnar epithelial cells during early embryogenesis (By similarity). In the nucleus
Gene References into Functions
  1. results demonstrate that human resting NK cells express Gal-3 at both gene and protein levels and that the Gal-3 expression can be modulated upon cytokine stimulation. In the same cells, Gal-3 always localizes intracellularly and functionally correlates with the degree of NK cell degranulation. PMID: 29248489
  2. Interaction between galectin-3 and its potential inhibitor, bergenin, was studied using computational methods. PMID: 30276553
  3. It has been reported that the Galectin-3/NuMA interaction is functionally important for the spindle pole organization; spindle pole cohesion requires glycosylation-mediated localization of NuMA. PMID: 28469279
  4. The Mac-2-binding protein glycosylation isomer (M2BPGi), which is also known as Wisteria floribunda agglutinin-positive human Mac-2-binding protein, was recently established as a glycol-biomarker of liver fibrosis in patients with chronic hepatitis C with a unique fibrosis-related glycoalteration. PMID: 30128700
  5. Higher plasma galectin-3 levels were associated with an elevated risk of developing incident chronic kidney disease, particularly among those with hypertension. PMID: 28865675
  6. Pre-interventional plasma Galectin-3 levels are associated with left ventricular reverse remodeling and with clinical outcome after percutaneous mitral valve repair. PMID: 29678512
  7. Galectin-3 is significantly associated with functional capacity, cardiac function and adverse cardiovascular events in adults with congenital heart defects. PMID: 28942393
  8. Gene expression was analyzed for miR-1, miR-21, and galectin-3 in hypertensive patients with symptomatic heart failure and left ventricular hypertrophy. PMID: 29905364
  9. Serum expression of miR-1 and miR-21, and the concentration of gal-3 in systolic heart failure patients with different degrees of left ventricular dilatation. PMID: 29905365
  10. Serum galectin-3 is associated with coronary atherosclerosis and obstructive sleep apnoea syndrome (OSAS) severity in OSAS patients. PMID: 28150280
  11. Study demonstrates that mesenchymal stromal cells (MSC)-derived LGALS3 may be critical for important biological pathways for MSC homeostasis and for regulating AML cell localization and survival in the leukemia microenvironmental niche. PMID: 29655803
  12. Low expression of galectin-3 was detected in all patients with malignant gastrointestinal tumors irrespective of the presence of eosinophilia. PMID: 29926280
  13. These findings highlight a new role for Galectin 3 as a non-classic RNA-binding protein that regulates MUC4 mRNA post-transcriptionally. PMID: 28262838
  14. Galectin-3 is superior to sST2 in distinguishing HFpEF from controls and HFrEF. PMID: 30039808
  15. erum Gal-3 levels were significantly higher in breast cancer (BC) patients and did not significantly differ according to clinical and tumoral characteristics of patients. Furthermore, there was no difference in Gal-3 levels between breast patients with and without metastatic disease. PMID: 30249872
  16. Gal3 expression in regional lymph nodes might be associated with oral squamous cell carcinomas progression. The increased Gal3 expression in regional lymph nodes of larger tumors underlines the need of immunomodulatory treatment concepts in early-stage oral squamous cell carcinomas . Blocking of Gal3 might be a therapeutic option in oral cancer. PMID: 30115022
  17. High Gal-3 serum levels predict fibrosis of the atrial appendage. PMID: 28079145
  18. this study reviews the role of galectin-3 in Atrial Fibrillation mechanisms and its potential therapeutic implications. PMID: 29587379
  19. Our findings provide evidence that allele C of rs4652 and allele T of rs11125 in the galectin-3 gene may be risk factors for cervical cancer. PMID: 28848207
  20. High GAL-3 expression is associated with Salivary Gland Tumor. PMID: 29580041
  21. Galectin-3 is greatly reduced in patients with cutaneous lupus lesions compared with healthy controls, which may contribute to the recruitment of inflammatory cells in the skin. PMID: 29058991
  22. Progesterone receptor, EGFR, and galectin-3 are expressed differentially in uterine smooth muscle tumors. PMID: 29729689
  23. Galectin-3 belongs to a class of inflammatory mediators that is associated with the degree of myocardial inflammation and fibrosis. It is related to the severity of myocardial ischemia and is negatively correlated with the cardiac ejection fraction. PMID: 29287900
  24. Increased GAL-3 levels are an independent predictor of all-cause mortality in hemodialysis patients. PMID: 26787685
  25. High GAL3 expression is associated with oral squamous cell carcinomas. PMID: 29284429
  26. High expression level of Galectin-3 and low expression level of TRAIL were found to be positively correlated with the shorter median survival time and overall survival time. PMID: 28925481
  27. Galectin-3 is overexpressed in patients with thyroid nodules, and can be used for diagnostic imaging and therapeutic targeting of cancer patients. (Review) PMID: 29393868
  28. With emerging evidence to support the function and application of galectin3, the current review aims to summarize the latest literature regarding the biomarker characteristics and potential therapeutic application of galectin3 in associated diseases. PMID: 29207027
  29. Our results indicate that concomitant stimulation and colocalization of galectin-3 with CD147 are associated with increased gelatinolytic activity in the actively ulcerating human cornea PMID: 29340650
  30. Galectin-3 can be used as a biomarker for the prognosis evaluation of acute heart failure, and its combined analysis can increase the predictive value of NT-proBNP PMID: 29077153
  31. Galectin has been identified as a proinflammatory protein and modulates immune responses either as damage-associated molecular patterns or as pattern recognition receptors. PMID: 28828226
  32. Gal-3 was found to be significantly higher in the stroma of patients with H. pylori infection, mainly on Cag-A positive H. pylori, with chronic gastritis. PMID: 28939284
  33. The present study demonstrates a relationship between galectin-3 levels and total body fat, abdominal fat, body fat distribution, cardiac size and geometry, and increase in total body fat over 2 years in young children. PMID: 29327139
  34. Results suggest that galectin-3 could help to monitor the risk of short-term mortality in unselected patients with acute heart failure (AHF) attended in the emergency department (ED). PMID: 28406038
  35. Report establishes the functional significance of Gal-3 as a broad-spectrum upstream effector in osteoarthritis (OA). A positive correlation between cartilage degeneration and Gal-3 positivity in chondrocytes and the ECM was found. PMID: 27982117
  36. the secretion of galectin-3 as a novel mechanism for osteoblasts to control osteoclastogenesis and to maintain trabecular bone homeostasis independently of the RANKL/OPG-axis. PMID: 28822790
  37. Gal-3 plasma concentration was significantly higher in pulmonary arterial hypertension patients. PMID: 28826890
  38. Galectin-3 was associated with incident ischaemic stroke in younger but not older individuals. PMID: 28872212
  39. As MUC1 and galectin-3 are both commonly overexpressed in most types of epithelial cancers, their interaction and impact on EGFR activation likely makes important contribution to EGFR-associated tumorigenesis and cancer progression. PMID: 28731466
  40. serum Gal-3 is increased in Acute exacerbation of chronic obstructive pulmonary disease patients. PMID: 28947730
  41. High serum levels of galectin-3 were found in patients with schizophrenia compared with that in controls. PMID: 28698921
  42. N-linked glycoprotein maturation is not required for Gal-3 transport from the cytosol to the extracellular space, but is important for cell surface binding. Additionally, secreted Gal-3 is predominantly free and not packaged into extracellular vesicles. These data support a secretion pathway independent of N-linked glycoproteins and extracellular vesicles. PMID: 28775154
  43. NRG1 and Gal-3 were significantly more elevated in cancer patients than in healthy controls. PMID: 28430337
  44. discovery of site specific N-glycosylation changes of LGALS3BP in association of PDAC may provide useful clues to facilitate cancer detection or phenotype stratification PMID: 28627758
  45. Our findings establish gal-3 as a molecular regulator of the JAG1/Notch-1 signaling pathway and have direct implications for the development of strategies aimed at controlling tumor angiogenesis. PMID: 28533486
  46. findings reveal that differential levels of Gal-3 and Gal-8 expression and recruitment to Group A streptococcus (GAS) between epithelial cells and endothelial cells may contribute to the different outcomes of GAS elimination or survival and growth of GAS in these two types of cells. PMID: 28743815
  47. The methylation frequency of the galectin-3 promoter was significantly higher while galectin-3 mRNA was lower in acute-on-chronic hepatitis B liver failure (ACHBLF) than in chronic hepatitis B and healthy controls. The results suggest that hypermethylation of the galectin-3 promoter might be an early biomarker for predicting disease severity and prognosis in patients with ACHBLF. PMID: 28185839
  48. Serum Gal-3 and Nox4 levels were significantly elevated and correlated in 26 human pulmonary arterial hypertension patients when compared with 14 age- and sex-matched healthy controls. PMID: 28431936
  49. These results demonstrate Tsc2-deficient mesenchymal progenitors cause aberrant morphogenic signals, and identify an expression signature including Lgals3 relevant for human disease of TSC1/TSC2 inactivation and mTORC1 hyperactivity. PMID: 28695825
  50. Galectin-3 is a possible immunological target molecule of the pathogenic auto-antibodies PMID: 27339072
  51. Higher levels of serum galectin-3 were independently associated with increased risk of death or major disability after stroke onset, suggesting that galectin-3 may have prognostic value in poor outcomes of ischemic stroke. PMID: 29229724
  52. galectin-3 is dynamically overexpressed in response to acute myocardial infarction-induced cardiac remodelling. PMID: 28094123
  53. Galectin-3 levels in serum were increased in patients with early undifferentiated arthritis of pre-rheumatoid arthritis origin. PMID: 28446218
  54. galectin-3 is an important regulator of hTERT expression and telomeric activity in gastric tumorigenesis PMID: 27494887
  55. Data show positive associations of relative Gal-3 and relative PSA levels in prostate cancer patients, notably at early clinical time course. PMID: 27741512
  56. The Notch signaling pathway was strongly activated by galectin-3 overexpression in A2780 ovarian cancer cells. PMID: 27626163
  57. thyroid nodule stiffness is correlated with fibrosis and expression of Gal-3 and FN-1 PMID: 27809694
  58. Gal-3 levels were measured at admission in 80 consecutive patients with symptomatic degenerative Aortic Stenosis (AS). The inverse glomerular filtration rate-Gal-3 relationship underlies a weak association between Gal-3 and adverse outcome in patients with degenerative AS referred for invasive therapy irrespective of type of treatment employed. PMID: 28468272
  59. Available experimental binding affinities for a small number of the tested compounds show very good agreement with the calculated energies and provide the rational approach for design of Gal-3 ligands with even higher affinity. PMID: 27939933
  60. An interruption of O-glycans extension caused by ST6GalNAc-I enzymatic activity alters galectin-3 subcellular location, leading to gastric tumor cell resistance to chemotherapeutic drugs. PMID: 27835877
  61. studied biomarkers do not predict arrhythmia recurrence after catheter ablation. Left atrial voltage is an independent predictor of recurrence, whether the left atrium is mapped in atrial fibrillation or sinus rhythm PMID: 29293545
  62. Here the authors show that galectin-3 secreted by tumours binds both glycosylated IFNgamma and glycoproteins of the tumour extracellular matrix, thus avoiding IFNgamma diffusion and the formation of an IFNgamma-induced chemokine gradient required for T cell infiltration. PMID: 28986561
  63. Evaluation of galectin-7 could help guide postsurgical management for non-metastatic ccRCC patients. PMID: 27259255
  64. The aim of this study was to investigate the association between myocardial fibrosis and plasma galectin-3 level in patients with primary aldosteronism. PMID: 27190071
  65. We have validated the vectors and confirmed self-association of AHCY, AHCYL1, and galectin-3. In a high-throughput BiFC screen, we identified new AHCY interaction partners: galectin-3 and PUS7L. We also describe additional steps in protein interaction analysis, applied for AHCY-galectin-3 interaction PMID: 27455993
  66. this study demonstrated that increased galectin-3 level was an independent unfavorable factor for OS in patients with non-M3 AML. PMID: 27736291
  67. plays a pivotal role in interstitial fibrosis and progression of chronic kidney disease [review] PMID: 27166158
  68. Our results indicate that the nuclear expression of Gal-3 has an essential role in the development of chromophobe carcinoma. The association with advanced tumor stage and nuclear grade suggests that this protein is an indicator of aggressiveness in the chromophobe subtype, thus targeting anti-nuclear transport may prove an effective therapy for this particular group of patients. PMID: 29277781
  69. regulation of gal-3 expression was strongly correlated with runx2 transcription factor in human thyroid carcinoma. PMID: 28390192
  70. Intra- and intermolecular interactions of human galectin-3 have been described. PMID: 26911284
  71. Overexpression of Cytogaligin reduces alpha-Synuclein dimerization raising a possible role in the evolution of alpha-Synuclein aggregation, a key molecular event underlying the pathogenesis of Parkinson's disease. PMID: 29137980
  72. Study reports genotyping of 4 previously identified SNPs in LGALS3 gene, in clinically unrelated patients with dilated cardiomyopathy (DCM). Results show that: 2 of the SNP variants were associated with low susceptibility of DCM; the AA genotype might be associated with lower left ventricular ejection fraction; and that none of the 4 SNPs had effect on overall or cardiovascular death in DCM patients. PMID: 29129812
  73. Gal-3, which is overexpressed in aortic valves from aortic stenosis patients, appears to play a central role in calcification in aortic stenosis. PMID: 27815266
  74. There was a significant inverse correlation between Gal-3 levels and glomerular filtration rate measured before and after heart transplant. PMID: 27614937
  75. high Gal-3BP plasma levels are associated with long-term mortality in coronary artery disease, but not with cardiac mortality or unstable plaque morphology PMID: 27295060
  76. High GAL3 expression is associated with drug resistance in gastric cancer. PMID: 26934444
  77. serum level of galectin-3 is increased in patients with early rheumatoid arthritis PMID: 28990250
  78. the present study contributes to our understanding of how complex HG and RG polysaccharides interact with Gal-3. PMID: 28986508
  79. Increased galectin-3 levels are associated with abdominal aortic aneurysm progression. Galectin-3 inhibition with modified citrus pectin prevented AAA development. PMID: 28982723
  80. galectin-3 may achieve multivalency through this multisite self-association mechanism facilitated by fuzzy interactions. PMID: 28893908
  81. Serum galectin-3 is elevated in coronary artery disease, but levels do not reflect severity of disease. PMID: 28795637
  82. Circulating CysC and Gal-3 were associated with greater left atrial dilatation in patients with heart failure with reduced left ventricular ejection fraction. PMID: 28830298
  83. Five data sets have been collected at three different neutron sources from galectin-3C crystals of various volumes. It was possible to merge two of these to generate an almost complete neutron data set for the galectin-3C-lactose complex. PMID: 27841752
  84. High serum galectin 3 expression is associated with Pancreatobiliary Cancer. PMID: 28870921
  85. Data suggest that galectin-3 and heterogeneous ribonucleoprotein particle component hnRNPA2B1 interact as members of the early splicing machinery. PMID: 27435226
  86. Increased Gal-3 reflects both increased neurohumoral activity and reduced glomerular filtration rate, but not myocardial function in patients with systolic heart failure. PMID: 27246703
  87. Cell surface Gal3 expression identifies a subset ofcancer stem cells in gastrointestinal cancers with high levels of stem cell characteristics, including chemoresistance. PMID: 27512958
  88. Galectin-3 and fibulin-1 levels are elevated in heart failure patients with impaired glucose metabolism. Reduced LV contractile reserve among HF patients with DM does not to have an independent impact on plasma Gal-3 and fibulin-1 levels. PMID: 28068900
  89. Galectin-3 may serve as a useful biomarker for evaluating the severity and outcomes in heart failure and in patients undergoing left ventricular assist device implantation. PMID: 27301475
  90. High galectin 3 expression is associated with colorectal cancer progression. PMID: 28146425
  91. High galactin 3 expression is associated with pancreatic cancer. PMID: 27617577
  92. a novel role of Gal3 as an initiator of inflammatory signaling in autoimmune cholangitis, mediating the activation of NOD-like receptor family, pyrin domain containing 3 inflammasome and inducing IL-17 proinflammatory cascades PMID: 27630169
  93. Galectin-3 levels and cystatin-C levels are independent predictors of 26-month mortality in patients with chronic heart failure PMID: 27119370
  94. The current study supports the tumor suppression role of galectin-3 in endometrial carcinoma PMID: 28215640
  95. Data suggest that galectin-3 (usually an elevated plasma/serum level of galectin-3) is emerging as a promising biomarker for outcome prediction and for guidance therapy in patients with acute coronary syndrome. [REVIEW] PMID: 28456545
  96. in at least some breast cancers, loss of Gal3 might be associated with EMT and cancer stemness-associated traits, predicts poor response to chemotherapy, and poor prognosis. PMID: 27687248
  97. Galectin-3 levels are higher in peripheral arterial disease. PMID: 27155290
  98. in combination with fusion proteins suitable for the design of diagnostic and therapeutic tools binding properties can be beneficially tuned. The resulting novel protein tools may be advantageous for potential galectin-3 directed applications in tumor diagnostics and therapy. PMID: 28104787
  99. Variation of GAL-3 serum levels related to single nucleotide polymorphism at +191 and +292 may constitute a susceptibility factor for respiratory tract infection and vaso-occlusion and respiratory tract infection frequency. PMID: 27603703
  100. Gal-3 was up-regulated in myocardial biopsies from aortic stenosis patients compared with controls. PMID: 28360193

Show More

Hide All

Subcellular Location Cytoplasm, Nucleus, Secreted
Tissue Specificity A major expression is found in the colonic epithelium. It is also abundant in the activated macrophages. Expressed in fetal membranes.
Database Links

HGNC: 6563

OMIM: 153619

KEGG: hsa:3958

STRING: 9606.ENSP00000254301

UniGene: Hs.531081

Most popular with customers


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1